Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cipla
Julphar
McKesson
Baxter
Daiichi Sankyo
Johnson and Johnson
Deloitte
Federal Trade Commission
US Department of Justice

Generated: January 18, 2018

DrugPatentWatch Database Preview

BAYER Company Profile

« Back to Dashboard

What is the competitive landscape for BAYER, and when can generic versions of BAYER drugs launch?

BAYER has one hundred and twenty-seven approved drugs.

There are sixty-two US patents protecting BAYER drugs and there have been two Paragraph IV challenges on BAYER drugs in the past three years.

There are one thousand six hundred and seventy-nine patent family members on BAYER drugs in seventy-six countries and one hundred and eighty-four supplementary protection certificates in sixteen countries.

Summary for BAYER
International Patents:1679
US Patents:62
Tradenames:110
Ingredients:75
NDAs:127

Drugs and US Patents for BAYER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare GADAVIST gadobutrol SOLUTION;INTRAVENOUS 201277-002 Mar 14, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Hlthcare DESONATE desonide GEL;TOPICAL 021844-001 Oct 20, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Bayer Hlthcare KYLEENA levonorgestrel INTRAUTERINE DEVICE;INTRAUTERINE 208224-001 Sep 16, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bayer Hlthcare MYCELEX clotrimazole TROCHE/LOZENGE;ORAL 018713-001 Jun 17, 1983 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-001 Oct 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Bayer Pharms AZLIN azlocillin sodium INJECTABLE;INJECTION 062388-002 Sep 8, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Hlthcare CIPRO ciprofloxacin hydrochloride TABLET;ORAL 019537-002 Oct 22, 1987 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Hlthcare KYLEENA levonorgestrel INTRAUTERINE DEVICE;INTRAUTERINE 208224-001 Sep 16, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 022283-001 Jun 17, 2013 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for BAYER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Pharms MYCELEX-G clotrimazole TABLET;VAGINAL 019069-001 Apr 19, 1985 ➤ Subscribe ➤ Subscribe
Bayer Hlthcare PRECOSE acarbose TABLET;ORAL 020482-001 Sep 6, 1995 ➤ Subscribe ➤ Subscribe
Bayer Hlthcare BEYAZ drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022532-001 Sep 24, 2010 ➤ Subscribe ➤ Subscribe
Bayer Hlthcare BEYAZ drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022532-001 Sep 24, 2010 ➤ Subscribe ➤ Subscribe
Bayer Hlthcare CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 019857-001 Dec 26, 1990 ➤ Subscribe ➤ Subscribe
Bayer Pharms BAYCOL cerivastatin sodium TABLET;ORAL 020740-003 Jun 26, 1997 ➤ Subscribe ➤ Subscribe
Bayer Hlthcare ULTRAVIST (PHARMACY BULK) iopromide INJECTABLE;INJECTION 021425-003 Mar 12, 2004 ➤ Subscribe ➤ Subscribe
Bayer Hlthcare CIPRO ciprofloxacin hydrochloride TABLET;ORAL 019537-002 Oct 22, 1987 ➤ Subscribe ➤ Subscribe
Bayer Hlthcare MAGNEVIST gadopentetate dimeglumine INJECTABLE;INJECTION 019596-001 Jun 2, 1988 ➤ Subscribe ➤ Subscribe
Bayer Pharms BAYCOL cerivastatin sodium TABLET;ORAL 020740-004 Jun 26, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BAYER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Foam 15% ➤ Subscribe 9/14/2017
➤ Subscribe Tablets 40 mg ➤ Subscribe 9/27/2016
➤ Subscribe Tablets 0.25 mg/0.5 mg ➤ Subscribe 1/8/2015
➤ Subscribe Tablets 200 mg ➤ Subscribe 2/28/2014
➤ Subscribe Injection 1.6 mg/mL ➤ Subscribe 2/7/2014
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 11/13/2012
➤ Subscribe Tablets 3 mg/0.03 mg/0.451 mg and 0.451 mg ➤ Subscribe 9/28/2012
➤ Subscribe Gel 15% ➤ Subscribe 7/27/2012
➤ Subscribe Orally Disintegrating Tablets 10 mg ➤ Subscribe 12/22/2011
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 11/21/2011
➤ Subscribe Gel 0.05% ➤ Subscribe 12/1/2010
➤ Subscribe Tablets 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg ➤ Subscribe 10/22/2010
➤ Subscribe Capsules 20 mg/1100 mg ➤ Subscribe 4/20/2010
➤ Subscribe Oral Suspension 250 mg/5 mL and 500 mg/ 5 mL ➤ Subscribe 10/16/2009
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 9/4/2009
➤ Subscribe Tablets 5 mg ad 10 mg ➤ Subscribe 7/10/2009
➤ Subscribe Tablets 20 mg ➤ Subscribe 3/5/2009
➤ Subscribe Tablets 0.5 mg/1 mg ➤ Subscribe 12/26/2007
➤ Subscribe Tablets 3 mg/0.02 mg ➤ Subscribe 9/29/2006
➤ Subscribe Transdermal System 0.05 mg/day and 0.1 mg/day ➤ Subscribe 9/12/2005
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 3/22/2005
➤ Subscribe Tablets 3 mg/0.03 mg ➤ Subscribe 1/7/2005
Premature patent expirations for BAYER

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe
➤ Subscribe ➤ Subscribe
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for BAYER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,645,803 Saccharide foamable compositions ➤ Subscribe
5,798,092 Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production ➤ Subscribe
9,452,082 Inserter ➤ Subscribe
7,314,871 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension ➤ Subscribe
8,298,515 Vitamin formulation ➤ Subscribe
RE45198 Omeprazole solution and method for using same ➤ Subscribe
6,121,465 Process for production drospirenone and intermediate products of the process ➤ Subscribe
9,592,245 Very low-dosed solid oral dosage forms for HRT ➤ Subscribe
8,629,128 Vitamin formulation ➤ Subscribe
9,050,253 Oleaginous pharmaceutical and cosmetic foam ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for BAYER Drugs

Supplementary Protection Certificates for BAYER Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
9 13-2013 Slovakia ➤ Subscribe FIRST REGISTRATION NO/DATE: EU/1/13/858, 20130826
2004005 Lithuania ➤ Subscribe PRODUCT NAME: INSULIN DETEMIR
0140015 00109 Estonia ➤ Subscribe PRODUCT NAME: RIOTSIGUAAT;REG NO/DATE: K(2014)2152 (LOPLIK) 31.03.2014
1663978/01 Switzerland ➤ Subscribe FORMER OWNER: BAYER HEALTHCARE LLC, US
35/2006 Austria ➤ Subscribe PRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON
5 5014-2014 Slovakia ➤ Subscribe PRODUCT NAME: RIOCIGUAT; REGISTRATION NO/DATE: EU/1/13/907 20140327
C/GB08/005 United Kingdom ➤ Subscribe SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
0673 Netherlands ➤ Subscribe PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
00620 Netherlands ➤ Subscribe PRODUCT NAME: REGORAFENIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/858 20130826
C/GB12/058 United Kingdom ➤ Subscribe PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Deloitte
Novartis
Cerilliant
Julphar
UBS
Moodys
Accenture
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot